AMS reports a 29% revenue growth in 2025 and a 10% increase in dividends

LootboxPhobia · 2026-03-18T07:24:45+00:00

UK wound care device manufacturer AMS announced 2025 results with revenue growth of 29% and adjusted EBITDA growth of 24%. The company projects 2026 revenue to reach £245.3 million, with strong growth in the surgical division, recovery in the wound care business, and a 10% dividend increase.

LootboxPhobia

2026-03-18 07:24:45

Abstract generation in progress

Investing.com — UK-based wound care device manufacturer AMS announced preliminary results for early 2025 on Wednesday, with revenue up 29%, driven by organic growth and acquisitions.

The company’s adjusted EBITDA for 2025 increased by 24%, with adjusted diluted earnings per share (EPS) up 12% year-over-year. AMS’s full-year adjusted EPS was £0.12, with EPS of £0.05.

Adjusted pre-tax profit reached £33.9 million, compared to £17.8 million pre-tax profit.

The board proposed a 10% increase in the full-year dividend, citing confidence in the company’s outlook.

Looking ahead to 2026, AMS expects revenue to reach £245.3 million, with adjusted EBITDA of £55.2 million. The company anticipates its surgical division will continue to grow strongly, while the wound care division will see moderate growth.

Full-year contributions from the Peters Surgical and Syntacoll acquisitions boosted revenue and expanded the company’s product portfolio.

The surgical division performed well in adhesives, biosurgical devices, and sutures, with significant growth in the US and Asia-Pacific regions.

The wound care business recovered after restructuring, benefiting from new supply agreements and a focus on high-margin products.

AMS expects to receive multiple product approvals in adhesives, sutures, and collagen technology starting in 2026.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.